Atomwise vs Alan

Alan has a disclosed valuation of $5.8B, while Atomwise's valuation is not publicly available, making a direct size comparison difficult. Alan employs 500-1000 people.

Alan has raised more in total funding at $750M, compared to Atomwise's $219M — a gap of $531M. Combined, the two companies have completed 4 known funding rounds.

Alan leads with an Awaira Score of 83/100, while Atomwise sits at 53/100. That 30-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Atomwise was founded by Abraham Heifets in 2012. Alan was founded by Jean-Charles Samuelian in 2016. Visit each company's profile on Awaira for a full founder biography.

Atomwise: Atomwise is an artificial intelligence company focused on drug discovery and development, founded in 2012 and headquartered in the United States. The company uses AI and computational chemistry to identify and optimize potential drug candidates, reducing the time and cost associated with traditional pharmaceutical research methods. Atomwise's platform applies machine learning algorithms to screen vast chemical libraries and predict molecular interactions, enabling faster identification of promising compounds for various therapeutic areas including oncology, infectious diseases, and genetic disorders. The company has secured $219 million in total funding and operates at the Series B stage, though its current valuation remains undisclosed. Atomwise's approach combines physics-based molecular modeling with machine learning to simulate how potential drugs interact with disease targets. The platform has been applied to multiple drug discovery projects across both internal programs and partnerships with pharmaceutical companies and research institutions. Atomwise competes in the growing computational drug discovery sector alongside companies utilizing AI for pharmaceutical development. The company's technology addresses significant pain points in drug development, including extended timelines and high failure rates. Its trajectory reflects the increasing adoption of AI-driven approaches in healthcare and pharmaceutical industries, positioning it within a broader trend toward computational acceleration of biomedical research and development processes. Atomwise applies physics-informed machine learning to molecular simulation for drug discovery, combining computational chemistry with AI to accelerate preclinical pharmaceutical development. Alan: Alan is an AI-powered health insurance platform that combines employer group health insurance products with a digital health companion application, using AI to personalise member health recommendations, streamline claims processing, and provide on-demand access to telehealth and mental health resources. The Paris company holds full insurance carrier status in France, Belgium, and Spain, operating as a licensed insurer rather than a distribution intermediary.\n\nThe company raised approximately $220 million including a Series D round from investors including Temasek, Coatue, and Index Ventures, reaching a valuation of approximately $1.4 billion. Alan reports over half a million members across its markets, covering employees at several thousand companies including Stripe, Spendesk, and Vinted, with strong growth in SME employer sales driven by its digital-first enrolment and claims experience. The Alan app provides members with health navigation, symptom checking, and AI-generated health content in addition to insurance card and claims management functionality.\n\nAlan competes in the European digital health insurance market against traditional mutuals including Malakoff Humanis and AG2R La Mondiale, as well as digital health insurers including Henner and Oscar Health in the US context. Its vertical integration as a licensed insurer combined with a technology platform differentiates it from insurtechs that distribute existing insurer products through digital channels, giving Alan full control over the member experience and claims economics. The company is considered one of the most significant French technology companies building in regulated financial services.

Atomwise got there first, launching in 2012 — that's 4 years of extra runway. Alan didn't arrive until 2016. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Atomwise has about 75 employees; Alan has about 500-1000. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Atomwise and Alan compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.